Advert - Novartis – AUTH/3399/10/20

Conduct of a representative

Novartis voluntarily admitted that one of its representatives had failed to maintain high standards with regard to discussions about the recommendation for use of Piqray (alpelisib) with two clinicians held before the medicine had been granted a marketing authorisation. Novartis was ruled in breach of the following clauses of the Code:


Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 3.1 - Promoting an unlicensed medicine

Clause 9.1 - Failing to maintain high standards